.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Merck
Dow
Cerilliant
UBS
Cantor Fitzgerald
Mallinckrodt
Moodys
Fuji
Johnson and Johnson

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 079217

« Back to Dashboard

NDA 079217 describes DRONABINOL, which is a drug marketed by Akorn Inc, Insys Therap, and Svc Pharma, and is included in three NDAs. It is available from five suppliers. Additional details are available on the DRONABINOL profile page.

The generic ingredient in DRONABINOL is dronabinol. There are eleven drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the dronabinol profile page.

Summary for 079217

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Therapeutic Class:Antiemetics
Formulation / Manufacturing:see details

Pharmacology for NDA: 079217

Ingredient-typeCannabinoids

Medical Subject Heading (MeSH) Categories for 079217

Suppliers and Packaging for NDA: 079217

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DRONABINOL dronabinol CAPSULE;ORAL 079217 ANDA Akorn, Inc. 17478-761 17478-761-06 1 BOTTLE in 1 CARTON (17478-761-06) > 60 CAPSULE in 1 BOTTLE
DRONABINOL dronabinol CAPSULE;ORAL 079217 ANDA Akorn, Inc. 17478-762 17478-762-06 1 BOTTLE in 1 CARTON (17478-762-06) > 60 CAPSULE in 1 BOTTLE

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength2.5MG
Approval Date:Jun 20, 2014TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength5MG
Approval Date:Jun 20, 2014TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength10MG
Approval Date:Jun 20, 2014TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Chinese Patent Office
Cerilliant
Mallinckrodt
QuintilesIMS
Queensland Health
Boehringer Ingelheim
Federal Trade Commission
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot